Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.06. Which is the better fit depends on your goals.
| ADPT | VWO | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $61.24 |
52-Week Low | $10.24 | $49.54 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VWO (Vanguard FTSE Emerging Markets ETF) trades at $60.07, up 1.74% on the day, with a bullish technical signal from moving averages. The ETF maintains a low 0.06% expense ratio and a 2.4% dividend yield, positioning it as a cost-efficient emerging markets vehicle. Recent news highlights performance comparisons with competing funds and the impact of South Korea's exclusion from its index, which has contributed to underperformance relative to some peers year-to-date.
The outlook for VWO hinges on broad emerging market growth and its low-cost advantage, but faces risks from geopolitical tensions, index methodology excluding South Korea, and potential underperformance versus developed market funds. The ETF offers diversification but may lag during periods of US market strength or when specific excluded markets outperform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
